Our brochure gives you an insight into the work of the Fraunhofer CIMD: We present the indication area of immune diseases, our bundled expertise, the path from medical need to new drugs and our biobanks.
The development of a new drug must follow a multi-stage process that is required by law. On average, it takes more than 13 years from the initial idea to the first marketing approval. Most of this time is spent on studies to test the drug's efficacy and tolerability and to determine the most appropriate dosing protocol.
High-quality biomaterials are essential for conclusive, unbiased medical research. In the context of immune-mediated diseases, the collection of such materials is often a limiting factor. The biobanks of Fraunhofer IME, Fraunhofer IZI and Fraunhofer ITEM store blood, tissue, stool and urine samples. These biomaterials can be used for research purposes whenever needed.
Fraunhofer Cluster of Excellence Immune-Mediated Diseases